Terms: = Lung cancer AND CIITA, P33076, 4261, ENSG00000179583, MHC2TA, C2TA
21 results:
1. LncRNA-HOXC-AS2 regulates tumor-associated macrophage polarization through the STAT1/SOCS1 and STAT1/ciita pathways to promote the progression of non-small cell lung cancer.
Yin C; Li J; Li S; Yang X; Lu Y; Wang C; Liu B
Cell Signal; 2024 Mar; 115():111031. PubMed ID: 38168631
[TBL] [Abstract] [Full Text] [Related]
2. Convergence of YAP/TAZ, TEAD and TP63 activity is associated with bronchial premalignant severity and progression.
Ning B; Tilston-Lunel AM; Simonetti J; Hicks-Berthet J; Matschulat A; Pfefferkorn R; Spira A; Edwards M; Mazzilli S; Lenburg ME; Beane JE; Varelas X
J Exp Clin Cancer Res; 2023 May; 42(1):116. PubMed ID: 37150829
[TBL] [Abstract] [Full Text] [Related]
3. Limitations and perceived delays for diagnosis and staging of lung cancer in Portugal: A nationwide survey analysis.
Barata F; Fidalgo P; Figueiredo S; Tonin FS; Duarte-Ramos F
PLoS One; 2021; 16(6):e0252529. PubMed ID: 34086757
[TBL] [Abstract] [Full Text] [Related]
4. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan.
Chen CY; Huang CF; Cheng PN; Tseng KC; Lo CC; Kuo HT; Huang YH; Tai CM; Peng CY; Bair MJ; Chen CH; Yeh ML; Lin CL; Lin CY; Lee PL; Chong LW; Hung CH; Huang JF; Yang CC; Hu JT; Lin CW; Chen CT; Wang CC; Su WW; Hsieh TY; Lin CL; Tsai WL; Lee TH; Chen GY; Wang SJ; Chang CC; Mo LR; Yang SS; Wu WC; Huang CS; Hsiung CK; Kao CN; Tsai PC; Liu CH; Lee MH; Liu CJ; Dai CY; Kao JH; Chuang WL; Lin HC; Yu ML
Liver Int; 2021 Jun; 41(6):1265-1277. PubMed ID: 33655714
[TBL] [Abstract] [Full Text] [Related]
5. MHC class I transactivator NLRC5 in host immunity, cancer and beyond.
Cho SX; Vijayan S; Yoo JS; Watanabe T; Ouda R; An N; Kobayashi KS
Immunology; 2021 Mar; 162(3):252-261. PubMed ID: 32633419
[TBL] [Abstract] [Full Text] [Related]
6. Disease-related cellular protein networks differentially affected under different EGFR mutations in lung adenocarcinoma.
Nishimura T; Nakamura H; Yachie A; Hase T; Fujii K; Koizumi H; Naruki S; Takagi M; Matsuoka Y; Furuya N; Kato H; Saji H
Sci Rep; 2020 Jul; 10(1):10881. PubMed ID: 32616892
[TBL] [Abstract] [Full Text] [Related]
7. Temporal trend of arsenic in outdoor air PM
Mao X; Hu X; Wang Y; Xia W; Zhao S; Wan Y
Environ Sci Pollut Res Int; 2020 Jun; 27(17):21654-21665. PubMed ID: 32279249
[TBL] [Abstract] [Full Text] [Related]
8. Expanding the clinicopathologic and molecular spectrum of BCOR-associated sarcomas in adults.
Yoshida A; Arai Y; Hama N; Chikuta H; Bando Y; Nakano S; Kobayashi E; Shibahara J; Fukuhara H; Komiyama M; Watanabe SI; Tamura K; Kawai A; Shibata T
Histopathology; 2020 Mar; 76(4):509-520. PubMed ID: 31647130
[TBL] [Abstract] [Full Text] [Related]
9. Finnish sauna bathing does not increase or decrease the risk of cancer in men: A prospective cohort study.
Laukkanen JA; Mäkikallio TH; Khan H; Laukkanen T; Kauhanen J; Kunutsor SK
Eur J Cancer; 2019 Nov; 121():184-191. PubMed ID: 31590079
[TBL] [Abstract] [Full Text] [Related]
10. Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.
Shah N; Mohammad AS; Saralkar P; Sprowls SA; Vickers SD; John D; Tallman RM; Lucke-Wold BP; Jarrell KE; Pinti M; Nolan RL; Lockman PR
Pharmacol Res; 2018 Jun; 132():47-68. PubMed ID: 29604436
[TBL] [Abstract] [Full Text] [Related]
11. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
Briere D; Sudhakar N; Woods DM; Hallin J; Engstrom LD; Aranda R; Chiang H; Sodré AL; Olson P; Weber JS; Christensen JG
Cancer Immunol Immunother; 2018 Mar; 67(3):381-392. PubMed ID: 29124315
[TBL] [Abstract] [Full Text] [Related]
12. [Treating cancer-related Fatigue after Chemotherapy in lung cancer Patients by Yiqi Jianpi Recipe: a Clinical Study].
Wang X; You J
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Sep; 35(9):1069-73. PubMed ID: 26591361
[TBL] [Abstract] [Full Text] [Related]
13. Selective modulation of MHC class II chaperons by a novel IFN-γ-inducible class II transactivator variant in lung adenocarcinoma A549 cells.
Chiu BL; Li CH; Chang CC
Biochem Biophys Res Commun; 2013 Oct; 440(1):190-5. PubMed ID: 24055710
[TBL] [Abstract] [Full Text] [Related]
14. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes.
Pollack BP; Sapkota B; Cartee TV
Clin Cancer Res; 2011 Jul; 17(13):4400-13. PubMed ID: 21586626
[TBL] [Abstract] [Full Text] [Related]
15. The role of surgery in clinical management of patients with metastatic papillary renal cell carcinoma.
Steiner T; Kirchner H; Siebels M; Doehn C; Heynemann H; Varga Z; Rohde D; Schubert J; Jocham D; Stief C; Fornara P; Hofmann R; Loening S; Roigas J
J Cancer Res Clin Oncol; 2010 Jun; 136(6):905-10. PubMed ID: 20012752
[TBL] [Abstract] [Full Text] [Related]
16. Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition.
Berghuis D; de Hooge AS; Santos SJ; Horst D; Wiertz EJ; van Eggermond MC; van den Elsen PJ; Taminiau AH; Ottaviano L; Schaefer KL; Dirksen U; Hooijberg E; Mulder A; Melief CJ; Egeler RM; Schilham MW; Jordanova ES; Hogendoorn PC; Lankester AC
J Pathol; 2009 Jun; 218(2):222-31. PubMed ID: 19274709
[TBL] [Abstract] [Full Text] [Related]
17. Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the ciita transcription Implication of ciita in tumor and metastasis development.
Shi B; Vinyals A; Alia P; Broceño C; Chen F; Adrover M; Gelpi C; Price JE; Fabra A
Int J Biochem Cell Biol; 2006; 38(4):544-62. PubMed ID: 16343978
[TBL] [Abstract] [Full Text] [Related]
18. Complicated mechanisms of class II transactivator transcription deficiency in small cell lung cancer and neuroblastoma.
Yazawa T; Ito T; Kamma H; Suzuki T; Okudela K; Hayashi H; Horiguchi H; Ogata T; Mitsui H; Ikeda M; Kitamura H
Am J Pathol; 2002 Jul; 161(1):291-300. PubMed ID: 12107114
[TBL] [Abstract] [Full Text] [Related]
19. MHC class II-deficient tumor cell lines with a defective expression of the class II transactivator.
Naves R; Lennon AM; Barbieri G; Reyes L; Puga G; Salas L; Deffrennes V; Rosemblatt M; Fellous M; Charron D; Alcaïde-Loridan C; Bono MR
Int Immunol; 2002 May; 14(5):481-91. PubMed ID: 11978778
[TBL] [Abstract] [Full Text] [Related]
20. Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer.
Yazawa T; Kamma H; Fujiwara M; Matsui M; Horiguchi H; Satoh H; Fujimoto M; Yokoyama K; Ogata T
J Pathol; 1999 Jan; 187(2):191-9. PubMed ID: 10365094
[TBL] [Abstract] [Full Text] [Related]
[Next]
